Promoting global health: Utilizing WHO to integrate public health, innovation and intellectual property

Drug Discovery Today

Volumn 17, Issue 23-24, 2012, Pages 1254-1257

  MacKey, Tim K ^a,b   Liang, Bryan A ^a,c,d  

^a CALIFORNIA WESTERN SCHOOL OF LAW   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of California at San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; IMATINIB;

DEVELOPING COUNTRY; FUNDING; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE POLICY; HEALTH PROMOTION; HUMAN; PATENT; PUBLIC HEALTH SERVICE; RESOURCE MANAGEMENT; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 84870358313     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.06.012     Document Type: Short Survey

References (37)

1. T.K. Mackey, and B.A. Liang The global counterfeit drug trade: patient safety and public health risks J. Pharm. Sci. 100 2011 4571 4579
2. World Health Organization Public Health Innovation and Intellectual Property Rights 2006 Available from: http://www.who.int/intellectualproperty/ documents/thereport/ENPublicHealthReport.pdf
3. World Health Organization and World Trade Organization WTO Agreements & Public Health 2002 Available from: http://www.wto.org/english/res-e/ publications-e/wto-agree-health-e.htm
4. World Health Organization Managing the effect of TRIPS on availability of priority vaccines Bull. World Health Organ. 84 2006 360 365
5. R.D. Smith Trade, TRIPS, and pharmaceuticals Lancet 373 2009 684 691
6. Medicines Patent Pool. Who we are. Available from: < http://www.medicinespatentpool.org/who-we-are2/ >
7. All-Party Parliamentary Group on AIDS About the Treatment Timebomb 2009 Available from: http://www.appghivaids.org.uk/events/timebomb.html
8. P. Basu International patent law - boon or bane of biotech? Nat. Biotechnol. 23 2005 13 15 (Pubitemid 41724613)
9. UNITAID. UNITAID concerned over future of medicines access after EU-India FTA. Available from: < http://www.unitaid.eu/resources/news/releases/943- unitaid-approves-us-30-million-for-innovative-project-to-roll-out-ground- breaking-tuberculosis-test-at-reduced-cost >
10. B. Waning A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries J. Int. AIDS Soc. 13 2010 35
11. V. Kerry, and K. Lee TRIPS, the Doha Declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines? Global Health 3 2007 3
12. F.M. Abbott WTO TRIPS Agreement and Its Implications for Access to Medicines in Developing Countries 2002 Available from: http://www.iprcommission. org/papers/pdfs/study-papers/sp2a-abbott-study.pdf
13. Wall Street Journal Online. Going off patent. Available from: < http://online.wsj.com/public/resources/documents/info-pharma0712-sort.html >
14. International Federation of Pharmaceutical Manufacturers & Associations. About research & development. Available from: < http://www.ifpma.org/innovation/rd/about-research-development.html >
15. M. Dickson, and J.P. Gagnon Key factors in the rising cost of new drug discovery and development Nat. Rev. Drug Discov. 3 2004 417 429 (Pubitemid 38618124)
16. M. Moran Neglected disease research and development: how much are we really spending? PLoS Med. 6 2009 e1000030
17. S. Villa Orphan drug legislation: lessons for neglected tropical diseases Int. J. Health Plann. Manage. 24 2009 27 42
18. S.A. Maurer Choosing the right incentive strategy for research and development in neglected diseases Bull. World Health Organ. 84 2006 376 381
19. World Health Organization (2006) Public health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action. 59th World Health Assembly, Report No.: WHA59.24. Available from: < http://www.who.int/phi/Res59-R24-en.pdf >
20. World Health Organization (2009) Global strategy and plan of action on public health, innovation and intellectual property. 62nd World Health Assembly, Report No.: WHA62.16. Available from: < http://apps.who.int/gb/ebwha/pdf- files/A62/A62-R16-en.pdf >
21. World Health Organization. The global strategy and plan of action on public health, innovation and intellectual property (GSPOA). Available from: < http://www.who.int/phi/implementation/phi-globstat-action/en/index.html >
22. Consultative Expert Working Group. Consultative expert working group on research and development: financing and coordination. Available from: < http://www.who.int/entity/phi/PHI-cewg-inception-report-2011-en.pdf >
23. Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). Available from: < http://www.who.int/phi/news/cewg- 2011/en/ >
24. World Health Organization Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination 2012 Available from: http://www.who.int/phi/CEWG-Report-5-April-2012.pdf
25. S. Shashikant Member States to Discuss Expert Recommendations on Health R&D 2012 Available from: http://www.twnside.org.sg/title2/intellectual- property/info.service/2012/ipr.info.120501.htm
26. World Trade Organization Technical Cooperation Activities: Information from other Intergovernmental Organizations 2004 Available from: http://www.who.int/medicines/areas/policy/TechnicalCoopActivities.pdf
27. World Intellectual Property Organization. WHO, WIPO, WTO Trilateral Cooperation on Public Health, Intellectual Property and Trade. Available from: < http://www.wipo.int/globalchallenges/en/health/trilateral-cooperation.html >
28. World Health Organization WHO Research for Health Strategy Approved by the 63rd World Health Assembly 2011 Available from: http://www.who.int/rpc/ researchategy/en/
29. M. Chan Meeting the demand for results and accountability: a call for action on health data from eight global health agencies PLoS Med. 7 2010 e1000223
30. Bill and Melinda Gates Foundation. Grand Challenges in Global Health Grand Challenges Explorations. Available from: < http://www.gatesfoundation. org/global-health/Pages/grand-challenges-explorations.aspx >
31. UNCTAD Pharmaceutical Production/Supply Capacity 2002 Available from: http://www.unctad.org/templates/Page.asp?intItemID=4567&lang=1
32. A. Seiter HNP Brief #3 Pharmaceuticals: Local Manufacturing 2005 World Bank Available from: http://siteresources.worldbank.org/ HEALTHNUTRITIONANDPOPULATION/Resources/281627-1109774792596/HNPBrief-3.pdf
33. R. Bate Local Pharmaceutical Production in Developing Countries. Campaign for Fighting Diseases 2008 Available from: http://www.hks.harvard.edu/m-rcbg/ fellows/T-Christian-Study-Group/Session%204/Local-Pharmaceutical-Production.pdf
34. World Bank Health Systems Funding Platform. Available from: < http://web.worldbank.org/WBSITE/EXTERNAL/TOPICS/EXTHEALTHNUTRITIONANDPOPULATION/ EXTHSD/0,contentMDK:22299073∼pagePK:148956∼piPK:216618∼theSitePK: 376793,00.html >
35. D.P. Fidler, and L.O. Gostin The WHO pandemic influenza preparedness framework: a milestone in global governance for health JAMA 306 2011 200 201
36. J.M. Mueller Taking TRIPS to India - Novartis, patent law, and access to medicines N. Engl. J. Med. 356 2007 541 543 (Pubitemid 46220813)
37. D. Sridhar, and L.O. Gostin Reforming the World Health Organization JAMA 305 2011 1585 1586